Excellent analysis in @JAMA_current : #Biosimilars are nonpreferred over reference product at most health plans… https://t.co/zX2glQi7JD
Excellent analysis in @JAMA_current : #Biosimilars are nonpreferred over reference product at most health plans… https://t.co/zX2glQi7JD